Horsman Michael R
a Department of Experimental Clinical Oncology , Aarhus University Hospital , Aarhus , Denmark.
Int J Hyperthermia. 2016;32(1):14-22. doi: 10.3109/02656736.2015.1099169. Epub 2015 Nov 25.
There is now definitive clinical evidence that hyperthermia can successfully improve the response of certain human tumour types to radiation therapy, but, there is still the need for improvement. From a biological standpoint this can be achieved by either targeting the cellular or vascular components of tumours. Strategies include targeting the radiation DNA repair processes, improving drug delivery using nanoparticles, exploiting immunotherapy mechanisms, reducing tumour pH, or modifying the tumour vascular supply. All of these approaches have been combined with either hyperthermia or radiation in preclinical models and clear benefits in tumour response observed. But few of these methods have actually been combined with thermoradiotherapy. Furthermore, very few combinations have been tested in relevant normal tissue studies, despite the fact that it is the normal tissue response that controls the maximal heat or radiation treatment that can be applied. Here we review the most clinically relevant biological approaches that have been shown to enhance thermoradiotherapy, or have the potential to be applied in this context, and suggest how these should be moved forward into the clinic.
目前已有确凿的临床证据表明,热疗能够成功提高某些人类肿瘤类型对放射治疗的反应,但仍有改进的必要。从生物学角度来看,这可以通过靶向肿瘤的细胞成分或血管成分来实现。策略包括靶向辐射DNA修复过程、使用纳米颗粒改善药物递送、利用免疫治疗机制、降低肿瘤pH值或改变肿瘤血管供应。所有这些方法在临床前模型中均已与热疗或放疗相结合,并观察到肿瘤反应有明显改善。但实际上这些方法中很少有与热放疗相结合的。此外,尽管正常组织反应决定了可应用的最大热疗或放疗剂量,但在相关正常组织研究中测试的组合却非常少。在此,我们综述了已被证明可增强热放疗或有潜力应用于热放疗的最具临床相关性的生物学方法,并提出应如何将这些方法推进到临床应用中。